# Fusion Pharmaceuticals (AstraZeneca)

Source: https://onco.cc/companies/fusion-pharma/  
OnCo record `fusion-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Alpha-emitter company acquired by AstraZeneca ($2.4B, 2024); FPI-2265 (225Ac-PSMA-I&T) in phase 3.

## Summary

Fusion Pharmaceuticals, based in Hamilton, Ontario, is the alpha-emitter company acquired by AstraZeneca for 2.4 billion dollars in 2024, and its FPI-2265, an actinium-225 PSMA-I&T agent, is in phase 3. Its pipeline also includes FPI-2068, an EGFR by c-MET bispecific radioconjugate, and the company holds actinium-225 supply agreements. OnCo links it to the AlphaBreak trial of FPI-2265 and the AcTION trial of 225Ac-PSMA-617, to targeted alpha therapy, to the actinium-225 PSMA agents record and to the radiopharmaceutical roadmap. Whether actinium PSMA therapy can improve on lutetium PSMA therapy is the question AlphaBreak will answer. Actinium-225 PSMA agents have their own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Hamilton, ON
- Type: radiopharma
- Website: https://www.astrazeneca.com

## Sources

- Official website: https://www.astrazeneca.com

## Connected records

- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- drugs: [Actinium-225 PSMA agents](https://onco.cc/drugs/ac225-psma/)
- trials: [AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)](https://onco.cc/trials/alphabreak/)
- technologies: [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- roadmaps: [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://onco.cc/roadmaps/radiopharma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/fusion-pharma.json